Molecular Markers in Testicular Germ Cell Tumors – Objects of Clinical Research or Close to Becoming Clinical Tools?

The aim of this short review is to critically evaluate hitherto investigated molecular markers for testicular germ cell tumors. Molecular parameters have been clinically established as diagnostic and prognostic markers for a number of tumors; this has not yet been achieved for germ cell tumors. There are interesting prospects, however. Studies on the ribonucleoprotein telomerase, for example, have demonstrated a correlation between enzyme activity and chemotherapeutic drug sensitivity. Moreover, innovative treatment approaches target this reverse transcriptase via telomerase antisense RNA. Another potential diagnostic marker is the detection of circulating tumor cells, which correlated with an increased relapse rate in initial studies. There are also interesting possibilities for the germ-cell-tumor-specific isochromosome [i(12)p], which is helpful in the differential diagnosis of mediastinal masses. Here initial studies demonstrated a correlation between the copy number and resistance against chemotherapeutic drugs. Without prospective studies to validate data obtained thus far, neither these nor other parameters can be assessed as diagnostic and prognostic factors. Irrespective of their immediate clinical applicability, however, investigations on molecular alterations in testicular germ cell tumors will become the basis for a molecular-diagnostically oriented subclassification of tumors as well as for novel therapeutic approaches.

[1]  T. Soussi The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation , 2000, Annals of the New York Academy of Sciences.

[2]  D. Sleijfer,et al.  Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer , 2000, The Lancet.

[3]  R. Chaganti,et al.  Genetics and biology of adult human male germ cell tumors. , 2000, Cancer research.

[4]  J. Moul,et al.  Molecular Genetic Parameters in Pathogenesis and Prognosis of Testicular Germ Cell Tumors , 2000, European Urology.

[5]  S. Seal,et al.  Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours , 2000, Nature Genetics.

[6]  P. Albers,et al.  Risk factors for relapse in stage I non‐seminomatous germ‐cell tumors: Preliminary results of the German multicenter trial , 1999, International journal of cancer.

[7]  R. Ghossein,et al.  Review: polymerase chain reaction detection of micrometastases and circulating tumor cells: application to melanoma, prostate, and thyroid carcinomas. , 1999, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[8]  J. Nadeau,et al.  Susceptibility to testicular germ-cell tumours in a 129.MOLF-Chr 19 chromosome substitution strain , 1999, Nature Genetics.

[9]  H. Schmoll Treatment of testicular tumours based on risk factors. , 1999, Current opinion in urology.

[10]  N. Breslow,et al.  High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor. , 1999, Cancer research.

[11]  T. Isono,et al.  Detection of circulating testicular cancer cells in peripheral blood. , 1999, Cancer letters.

[12]  Monika Engelhardt,et al.  Telomerase activity in germ cell cancers and mature teratomas. , 1999, Journal of the National Cancer Institute.

[13]  R. Cote,et al.  Detection and clinical importance of micrometastatic disease. , 1999, Journal of the National Cancer Institute.

[14]  I. Bodrogi,et al.  mdm-2 expression in human testicular germ-cell tumors and its clinical value. , 1999, Anticancer research.

[15]  B. Hero,et al.  Telomerase activity distinguishes between neuroblastomas with poor prognosis , 1999 .

[16]  A. W. Boersma,et al.  Distinct p53‐independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines , 1999, International journal of cancer.

[17]  M. Hudson,et al.  Late effects of treatment for germ cell tumors during childhood and adolescence. , 1999, Journal of pediatric hematology/oncology.

[18]  B. Hero,et al.  Telomerase activity distinguishes between neuroblastomas with good and poor prognosis. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  D. Huhn,et al.  Detection of tumor cells in peripheral blood samples from patients with germ cell tumors using immunocytochemical and reverse transcriptase-polymerase chain reaction techniques , 1998, Bone Marrow Transplantation.

[20]  A. Giaccia,et al.  The complexity of p53 modulation: emerging patterns from divergent signals. , 1998, Genes & development.

[21]  G. Gyapay,et al.  A new human nm23 homologue (nm23‐H5) specifically expressed in testis germinal cells 1 , 1998, FEBS letters.

[22]  J. Niland,et al.  The MDM2 gene amplification database. , 1998, Nucleic acids research.

[23]  A. Weiss,et al.  Detection and characterization of carcinoma cells in the blood. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Toner Gc,et al.  Poor prognosis germ cell tumors: current status and future directions. , 1998 .

[25]  R. Chaganti,et al.  A genetic perspective of male germ cell tumors. , 1998, Seminars in oncology.

[26]  J. Moul,et al.  Immunohistochemical and mutational analysis of the p53 tumour suppressor gene and the bcl‐2 oncogene in primary testicular germ cell tumours , 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[27]  R. Motzer,et al.  Poor prognosis germ cell tumors: current status and future directions. , 1998, Seminars in oncology.

[28]  Candidate regions for testicular cancer susceptibility genes. The International Testicular Cancer Linkage Consortium. , 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[29]  K. Cornetta,et al.  Detection of germ cell tumor cells in apheresis products using polymerase chain reaction. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  R. Fimmers,et al.  MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis. , 1998, Cancer.

[31]  C. Lundsteen,et al.  Detection of chromosomal aberrations in seminomatous germ cell tumours using comparative genomic hybridization , 1997, Genes, chromosomes & cancer.

[32]  P. Hall,et al.  Risk of second malignant neoplasms among long-term survivors of testicular cancer. , 1997, Journal of the National Cancer Institute.

[33]  F. Mostofi,et al.  Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors. , 1997, The Journal of urology.

[34]  H. Juhl,et al.  Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. , 1997, Cancer research.

[35]  J. Double,et al.  Inhibition of telomerase activity by cisplatin in human testicular cancer cells. , 1997, European journal of cancer.

[36]  J. Serth,et al.  Alterations of the p53 tumor suppressor gene in carcinoma in situ of the testis , 1996, Cancer.

[37]  K. Pantel,et al.  Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. , 1996, Journal of the National Cancer Institute.

[38]  K. Pantel,et al.  Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases , 1996, The Lancet.

[39]  D. Forman,et al.  Candidate regions for a testicular cancer susceptibility gene , 1995 .

[40]  J. Moul,et al.  Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors. , 1995, The Journal of urology.

[41]  P. Goss,et al.  Loss of heterozygosity of tumor suppressor genes in testis cancer. , 1995, Cancer research.

[42]  H. Koga,et al.  Intracranial Germ Cell Tumors: Detection of p53 Gene Mutations by Single‐strand Conformation Polymorphism Analysis , 1995, Japanese journal of cancer research : Gann.

[43]  A. Levine,et al.  The p53 and mdm‐2 genes in human testicular germ‐cell tumors , 1995, Molecular carcinogenesis.

[44]  H. Gross,et al.  Model study detecting breast cancer cells in peripheral blood mononuclear cells at frequencies as low as 10(-7). , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Chaganti,et al.  Loss of heterozygosity identifies multiple sites of allelic deletions on chromosome 1 in human male germ cell tumors. , 1994, Cancer research.

[46]  V. Reuter,et al.  Frequent allelic deletions and loss of expression characterize the DCC gene in male germ cell tumors. , 1994, Oncogene.

[47]  F. Mostofi,et al.  Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. , 1994, The Journal of urology.

[48]  J W Moul,et al.  Immunohistochemical expression of P53 tumor suppressor gene protein in adult germ cell testis tumors: clinical correlation in stage I disease. , 1994, The Journal of urology.

[49]  V. Reuter,et al.  Allelic loss and somatic differentiation in human male germ cell tumors. , 1994, Oncogene.

[50]  V. Reuter,et al.  Loss of heterozygosity and decreased expression of NME genes correlate with teratomatous differentiation in human male germ cell tumors. , 1994, Biochemical and biophysical research communications.

[51]  D. Slamon,et al.  Mutations of the p53 gene are not detectable in human testicular tumors. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[52]  T. Ulbright,et al.  The correlation of P53 protein expression with proliferative activity and occult metastases in clinical stage I non-seminomatous germ cell tumors of the testis. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[53]  P. Meltzer,et al.  Molecular cytogenetic analysis of i(12p)‐negative human male germ cell tumors , 1993, Genes, chromosomes & cancer.

[54]  B. Gallie,et al.  Mutations of the p53 gene do not occur in testis cancer. , 1993, Cancer research.

[55]  R. Chaganti,et al.  Cytogenetics of male germ-cell tumors. , 1993, The Urologic clinics of North America.

[56]  G. Hanks,et al.  Seminoma of the testis: long-term beneficial and deleterious results of radiation. , 1992, International journal of radiation oncology, biology, physics.

[57]  K. Pittman,et al.  Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction , 1991, The Lancet.

[58]  K. Pantel,et al.  Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. , 1991, European journal of cancer.

[59]  C. Cordon-Cardo,et al.  Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[60]  E. Dmitrovsky,et al.  Genetic analysis as an aid in diagnosis for patients with midline carcinomas of uncertain histologies. , 1991, Journal of the National Cancer Institute.

[61]  E. Dmitrovsky,et al.  Cytogenetic and molecular analysis of human male germ cell tumors: Chromosome 12 abnormalities and gene amplification , 1990, Genes, chromosomes & cancer.

[62]  E. Dmitrovsky,et al.  Isochromosome of Chromosome 12: Clinically Useful Marker for Male Germ Cell Tumors , 1989 .

[63]  G. T. te Meerman,et al.  Chromosomal changes in human primary testicular nonseminomatous germ cell tumors. , 1989, Cancer research.

[64]  E. Dmitrovsky,et al.  Isochromosome of the short arm of chromosome 12: clinically useful markers for male germ cell tumors. , 1989, Journal of the National Cancer Institute.

[65]  N. B. Atkin,et al.  i(12p): specific chromosomal marker in seminoma and malignant teratoma of the testis? , 1983, Cancer genetics and cytogenetics.

[66]  N. B. Atkin,et al.  SPECIFIC CHROMOSOME CHANGE, i(12p), IN TESTICULAR TUMOURS? , 1982, The Lancet.

[67]  L. Einhorn,et al.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. , 1977, Annals of internal medicine.